Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 200
- Avg volume
- —
- Day's range
- $4.85 – $5.20
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
TFA Therapeutics, Inc. develops TFA-01 novel nonsteroidal anti-inflammatory drugs for pet medical care. It offers drugs in the areas of canine osteoarthritis, dermatitis, and feline stomatitis. The company serves customers in Taiwan, Japan, Greater China, and United States. TFA Therapeutics, Inc. was formerly known as Cordyceps Sunshine Biotech Holdings Co., Ltd. and changed its name to TFA Therapeutics, Inc. in July...
Show more
TFA Therapeutics, Inc. develops TFA-01 novel nonsteroidal anti-inflammatory drugs for pet medical care. It offers drugs in the areas of canine osteoarthritis, dermatitis, and feline stomatitis. The company serves customers in Taiwan, Japan, Greater China, and United States. TFA Therapeutics, Inc. was formerly known as Cordyceps Sunshine Biotech Holdings Co., Ltd. and changed its name to TFA Therapeutics, Inc. in July 2026. The company was incorporated in 2020 and is based in Taipei, Taiwan.
- Industry
- Packaged Foods
- Sector
- Consumer Defensive
- Phone
- 886 2 2748 9091
- Website
- https://www.tfabio.com
- Address
- No. 15, Lane 548, 6th Floor Ruiguang Road Neihu District, Taipei, Taiwan
Latest news
No headlines yet.
